Libeli (Chlormadinone Acetate, Ethinylestradiol)

Chlormadinone acetate is a progestin that suppresses the hypothalamic‑pituitary‑ovarian axis, preventing the luteinising hormone surge that triggers ovulation. Together with the estrogen ethinylestradiol, it also thickens cervical mucus and stabilises the endometrium, creating conditions that are unfavorable for sperm penetration and implantation.

The specific dosing regimen for Libeli is determined by the prescribing clinician based on the product’s labeling and the patient’s individual needs. Healthcare professionals select the appropriate tablet strength, schedule, and duration in accordance with local regulatory guidance.

Libeli is intended for use as a contraceptive and should not be taken during pregnancy. If pregnancy occurs, the medication should be discontinued. Limited data are available for breastfeeding; clinicians usually advise caution and may recommend alternative contraception while nursing.

To request Libeli, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Libeli contains chlormadinone acetate and ethinylestradiol, a progestin‑estrogen pairing similar to many other combined pills. Compared with alternatives, chlormadinone acetate offers a distinct progestogenic profile that may influence side‑effect patterns such as acne or lipid changes, but overall contraceptive efficacy is comparable when taken correctly.

Libeli tablets should be stored at ambient temperature, below 25 °C, in the original container. Keep them away from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

Libeli is taken orally, usually once daily at the same time each day, following the regimen specified on the product label. The tablets are swallowed whole with water and should be started according to the prescribing information, often on the first day of the menstrual period.

Serious but rare risks include venous thromboembolism such as deep‑vein thrombosis, pulmonary embolism, stroke and myocardial infarction. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be evaluated carefully before initiating therapy.

Libeli is contraindicated in women with known or suspected pregnancy, active or history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or in those over 35 who smoke. It should also be avoided in individuals with known hypersensitivity to any component of the formulation.